Proactive Cohort Management for Mastering Dose Escalation in Early-Phase Oncology Development

Dr. Abbott has expertise in hematology, oncology, and biomedical research, specializing in clinical trial strategy and medical monitoring. As Senior Medical Director at Allucent, he provides strategic guidance on clinical trials. He previously held leadership roles at ICON plc, Myriad Genetics, and Caris Life Sciences. Before transitioning to research, Dr. Abbott focused on hematologic malignancies, BMT, and medical oncology, serving on the faculty at the University of Colorado and St. Jude Children’s Research Hospital. He holds an MD, MBA, and MS in Finance and is board-certified in Hematology/Oncology, Pediatrics, and Hospice and Palliative Medicine.

Sandra Olthaf is Oncology/Hematology Global Operations Head, Global Project Leadership at Allucent, where she leads cross-functional project teams, manages oncology and hematology portfolios, and drives process optimization and client satisfaction within Clinical Trial Operations. With over 15 years of clinical oncology experience, she has successfully led global phase I–IV trials across immuno-oncology and hematologic oncology, ensuring operational excellence and high-quality delivery.

Rachel Kudgus Lokken, is Senior Director, Clinical Pharmacology at Allucent, where she is responsible for providing clinical pharmacology expertise across all phases of drug development. Dr. Kudgus Lokken has broad experience in pre-clinical and clinical pharmacology, pharmacokinetics, pharmacometrics, scientific/technical writing, and teaching.  She has worked in a variety of therapeutic areas with a focus in oncology and hematology, designing and executing early phase human trials. She leads clinical pharmacology contributions by preparing and reviewing clinical protocols, clinical study reports, clinical pharmacology strategic plans, INDs, clinical pharmacology and safety sections of NDAs, Investigator Brochures, FDA briefing packets, and other clinical and regulatory documents.

Titia Tjeenk Willink, MSc, is Sr. Project Director, Global Project Leadership at Allucent, with more than 15 years’ professional experience in the field of clinical research. Titia is responsible for the oversight of complex clinical trials, providing focused project management services to studies under her responsibility. She oversees the coordination and management of clinical trials by monitoring project trial status, timelines, and budgets, while ensuring a high level of customer satisfaction. Her focus is on hemato-oncology projects in various indications with a range of investigational drugs (including oral chemotherapy, immune-cell vaccine, monoclonal antibodies), from early phase/FIH to large international phase III studies.